<DOC>
	<DOCNO>NCT02021032</DOCNO>
	<brief_summary>The primary objective post-marketing study collect safety effectiveness data 5 year subject treat Prolieve® . The collection 5-year safety information use evaluate occurrence long-term side effect treatment . The collection long-term effectiveness data subject treat Prolieve® provide information long-term effect treatment time re- treatment ( treatment initiate BPH since Prolieve ' '' treatment , include second treatment Prolieve '' ) .</brief_summary>
	<brief_title>Post-Marketing Study Using PROLIEVE® Treatment Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Diagnosed symptomatic BPH . Peak Urine flow rate &lt; 12 ml/sec void volume &gt; 125mL . AUA symptom score value ≥9 ( 9 ) . Signed informed consent . Subjects whose pain response significantly decrease mean ( subject 's ability detect pain treatment safety mechanism ) . Subject history illness surgery might confound result study `` impede successful completion trial '' Subject history illness Prolieve® treatment may pose additional risk subject . Subject confirm suspected malignancy prostate Subject confirm suspected bladder cancer PSA &gt; 10 ng/mL Subject previous treatment prostate ( e.g. , surgery , balloon dilation , stent , laser , TUNA , Indigo prostatectomy ) and/or nonmetallic urogenital implant ( e.g. , penile prosthesis , artificial urinary sphincter ) Subject prostate weighing &lt; 20 &gt; 80g . Subject previous pelvic irradiation radial pelvic surgery Subject large , obstructive middle lobe Previous rectal surgery ( hemorrhoidectomy ) history rectal disease . Subject urethral stricture and/or bladder stone Active urinary tract infection . Subject neurogenic bladder and/or sphincter abnormality due Parkinson 's , multiple sclerosis , cerebrovascular accident ( CVA ) , diabetes , disease process . Residual bladder volume &gt; 250 mL measure ultrasound . Compromised renal function ( i.e. , serum creatinine level 1.8 mg/dL ) . Cardiac pacemaker metallic implant staple , etc . pelvic femoral area . Concomitant medicate follow : 1 . Bladder antispasmodic ( Ditropan Detrol ) within one week treatment , unless document evidence subject drug dose least three month stable void pattern . The drug dose alter discontinue entrance throughout study . 2 . 5alpha reductase inhibitor gonadotropin release hormonal analog . 3 . Alpha blocker , antidepressant , androgen , within one week treatment . Subject interested future fertility/fathering child . Subject full urinary retention . Subject bleed disorder liver dysfunction associate bleed disorder . Subject prostatic urethra length &lt; 1.2 cm &gt; 5.5 cm .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>BPH</keyword>
</DOC>